CYCCPCyclacel Pharmaceuticals, Inc.

Nasdaq cyclacel.com


$ 6.70 $ 0.00 (0 %)    

Tuesday, 14-May-2024 14:57:02 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 6.7
$ 6.70
$ 0.00 x 0
$ 0.00 x 0
$ 6.70 - $ 6.70
$ 5.21 - $ 22.20
34
na
3.35M
$ 0.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-29-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-05-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-28-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-30-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-29-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-12-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
39 11-12-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels -   - A Squamous Non-Small Cell Lung ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical...

Core News & Articles

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, Cyclacel or the Company)))), a biopharmaceutical company developing ...

Core News & Articles

 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a b...

Core News & Articles

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Typ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a bi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION